J&J Psoriasis Drug Approval ‘Another Negative’ For Valeant

On Thursday, the Food and Drug Administration approved Johnson & Johnson‘s (JNJ) new psoriasis drug, Tremfya.  Wells Fargo’s David Maris reiterated an Underperform rating on Valeant Pharmaceuticals (VRX) on Friday, calling the news “another  negative” for the company, which is about to launch its own psoriasis treatment. More from his note:   Pixabay In addition, VRX has […]
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>